<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background and purpose.  <z:hpo ids='HP_0001635'>Heart failure</z:hpo> and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> are associated with <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of cardiomyocytes, suggesting common abnormalities in pro-apoptotic cardiac molecules </plain></SENT>
<SENT sid="1" pm="."><plain>Activation of the receptor tyrosine kinase EphA2 causes <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro, and dysregulation of EphA2-depdendent signaling is implicated in LEOPARD and Noonan syndromes associated with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Molecular pathways and regulation of EphA2 signaling in the heart are poorly understood </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study was to elucidate the pathways of EphA2-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, a therapeutic strategy to prevent EphA2 activation and cardiac cell <z:hpo ids='HP_0011420'>death</z:hpo> was evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Experimental approach.  EphA2 signaling was studied in an established <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-1 cell model of drug-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Key results.  <z:mpath ids='MPATH_3'>Apoptosis</z:mpath> induced by <z:chebi fb="0" ids="4708">doxazosin</z:chebi> (EC(50) = 17.3 µmol/L) was associated with EphA2 activation through enhanced phosphorylation (2.2-fold, p = 0.031) </plain></SENT>
<SENT sid="7" pm="."><plain>Activation of pro-apoptotic downstream factors phospho-SHP-2 (3.9-fold, p = 0.007), phospho-p38 MAPK (2.3-fold, p = 0.007) and GADD153 (1.6-fold, p = 0.35) resulted in cleavage of caspase 3 </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, anti-apoptotic enzymes were suppressed (focal <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> kinase, -41%, p = 0.22; phospho-Akt, -78%, p = 0.002) </plain></SENT>
<SENT sid="9" pm="."><plain>SiRNA-mediated EphA2 inactivation mimicked pro-apoptotic effects of <z:chebi fb="0" ids="4708">doxazosin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, administration of <z:chebi fb="0" ids="16325">lithocholic acid</z:chebi> (LCA) protected from <z:mpath ids='MPATH_3'>apoptosis</z:mpath> through enhanced EphA2 protein levels and via prevention of EphA2 phosphorylation </plain></SENT>
<SENT sid="11" pm="."><plain>Conclusions and implications.  EphA2 phosphorylation and activation of SHP-2 are critical steps in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>Reduction of EphA2 phosphorylation by <z:chebi fb="0" ids="16325">lithocholic acid</z:chebi> may represent a novel approach for future anti-apoptotic treatment of <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>. © 2012 The Authors </plain></SENT>
<SENT sid="13" pm="."><plain>British Journal of Pharmacology © 2012 The British Pharmacological Society </plain></SENT>
</text></document>